EARGO INC (EAR)
US2700872086 - Common Stock
We assign a fundamental rating of 3 out of 10 to EAR. EAR was compared to 195 industry peers in the Health Care Equipment & Supplies industry. While EAR seems to be doing ok healthwise, there are quite some concerns on its profitability. EAR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year EAR has reported negative net income.
EAR had a negative operating cash flow in the past year.
In the past 5 years EAR always reported negative net income.
EAR had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
EAR's Return On Assets of -154.97% is on the low side compared to the rest of the industry. EAR is outperformed by 89.90% of its industry peers.
EAR has a Return On Equity of -239.84%. This is amonst the worse of the industry: EAR underperforms 82.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -154.97% | ||
| ROE | -239.84% | ||
| ROIC | N/A |
ROA(3y)-76.89%
ROA(5y)-90.17%
ROE(3y)-133.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EAR's Gross Margin of 41.94% is on the low side compared to the rest of the industry. EAR is outperformed by 63.13% of its industry peers.
In the last couple of years the Gross Margin of EAR has grown nicely.
The Profit Margin and Operating Margin are not available for EAR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.62%
GM growth 5Y3.34%
2. Health
2.1 Basic Checks
EAR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EAR has been increased compared to 1 year ago.
Compared to 5 years ago, EAR has more shares outstanding
There is no outstanding debt for EAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
EAR has an Altman-Z score of -13.28. This is a bad value and indicates that EAR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.28, EAR is not doing good in the industry: 82.83% of the companies in the same industry are doing better.
There is no outstanding debt for EAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.28 |
ROIC/WACCN/A
WACC9.84%
2.3 Liquidity
A Current Ratio of 3.22 indicates that EAR has no problem at all paying its short term obligations.
The Current ratio of EAR (3.22) is comparable to the rest of the industry.
A Quick Ratio of 2.97 indicates that EAR has no problem at all paying its short term obligations.
EAR has a Quick ratio (2.97) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.22 | ||
| Quick Ratio | 2.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 90.73% over the past year.
The Revenue has grown by 19.51% in the past year. This is quite good.
The Revenue has been growing by 41.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q96.77%
Revenue 1Y (TTM)19.51%
Revenue growth 3Y4.34%
Revenue growth 5Y41.27%
Revenue growth Q2Q4.55%
3.2 Future
Based on estimates for the next years, EAR will show a small growth in Earnings Per Share. The EPS will grow by 1.04% on average per year.
The Revenue is expected to grow by 6.88% on average over the next years.
EPS Next Y93.38%
EPS Next 2Y1.04%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year19.87%
Revenue Next 2Y6.88%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EAR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.04%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for EAR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EARGO INC
NASDAQ:EAR (2/15/2024, 7:00:01 PM)
After market: 2.6 +0.03 (+1.17%)2.57
-0.11 (-4.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap53.38M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -154.97% | ||
| ROE | -239.84% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.22 | ||
| Quick Ratio | 2.97 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)90.73%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y93.38%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.51%
Revenue growth 3Y4.34%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y